Biography

Atul Saluja, Ph.D. currently heads the Injectables MSAT platform within Sanofi’s Manufacturing & Supply (M&S) organization. His organization, spread over 10+ commercial production sites in 5 countries in EU and North America, ensures drug product industrialization, technology transfer, validation/PPQ, pre-approval inspections, and dossier support for Sanofi’s commercial and launch-ready programs. Atul joined Sanofi in January 2017 as part of the Biologics Drug Product team within the CMC organization. Over the past 7 years, Atul has led teams in various capacities engaged in the development of clinical and commercial products spanning multiple modalities and dosage forms, transferred products from laboratory to clinical and commercial manufacturing sites, enabled execution of validation campaigns, instituted LCM process changes and in working closely with drug product hubs in France and Germany helped implement workflow improvements through strategic initiatives covering a broad development space. Under his leadership and in collaboration with partners in M&S, the drug product teams successfully transferred and helped commercialize Nexviazyme®, Xenpozyme®, Enjaymo® Altuviiio® amongst others.

Before joining Sanofi, Atul held technical leadership roles in biologics drug product development at Bristol-Myers Squibb, KBI Biopharma, and Amgen. Atul holds a Ph.D. in Pharmaceutical Sciences from University of Connecticut.

Back to the Keynote Speaker page